To prevent discontinuation of antipsychotic medication in daily clinical practice among patients with early-phase schizophrenia, no difference was found in treatment with long-acting injectable (LAI) antipsychotic vs oral treatment concerning time to discontinuation. These findings were published in The Lancet Psychiatry.